

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 09, 2023

iTeos Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-39401
(Commission File Number)

84-3365066
(IRS Employer
Identification No.)

321 Arsenal Street
Watertown, Massachusetts
(Address of Principal Executive Offices)

02472
(Zip Code)

Registrant's Telephone Number, Including Area Code: 339 217 0161

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	ITOS	The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure.

On January 10, 2023, Michel Detheux, Ph.D., President and Chief Executive Officer of iTeos Therapeutics, Inc., will present at the 41st Annual J.P. Morgan Healthcare Conference (the "Conference"). The slides that will be presented by Dr. Detheux at the Conference are furnished with this report as Exhibit 99.1, which is incorporated herein by reference.

The information in this Item 7.01 is furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	iTeos Therapeutics, Inc. Presentation at the 41st Annual J.P. Morgan Healthcare Conference dated January 10, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

iTeos Therapeutics, Inc.

Date: January 9, 2023

By: /s/ Michel Detheux
Michel Detheux, Ph.D.
President and Chief Executive Officer



Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS January 2023

iteotherapeutics.com

Forward-Looking Statements



This presentation contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of our product candidates and combinations; the potential of TIGIT to be the next advance in cancer treatment; the potential of our biomarker to guide patient selection; our clinical plans and expected timelines, including the expectation to make significant progress in 2023 and that EOS-984 will enter into the clinic in mid-2023; our potential market opportunities; the potential benefits of our collaboration with GSK, including dostarlimab being the ideal combination partner for EOS-448; the potential to differentiate EOS-448 to win with the quality of our therapies, major indications and unique combinations; the expectation that 2023 will be a pivotal year for TIGIT and iTeos being ideally positioned to enter this year; and our expected cash runway into 2026.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos' control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; the data for our product candidates may not be sufficient to support regulatory approval; iTeos may encounter unanticipated costs or may expend cash more rapidly or more slowly than currently anticipated due to challenges and uncertainties inherent in product research and development and biologics manufacturing; the expected benefits and opportunities related to the agreement between iTeos and GSK may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in product research and development and manufacturing limitations; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos' control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, regulatory, court or agency decisions such as decisions by the United States Patent and Trademark Office with respect to patents that cover our product candidates and the impact of the COVID-19 pandemic; and those risks identified under the heading "Risk Factors" in iTeos' Quarterly Report on Form 10-Q for the nine months ended September 30, 2022 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets. Statements regarding the Company's cash runway do not indicate when the Company may access the capital markets.

Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. iTeos does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.




Better Immunotherapies to Improve the Lives of People with Cancer

Nasdaq: ITOS January 2023

iteostherapeutics.com




* As of September 30, 2022



EOS-448:
**Anti-TIGIT optimized for
immune cell activation**


Expansive and unique development
plan with GSK



Inupadenant & EOS-984:
**Designed to fully exploit
the adenosine pathway**

Leverage deep understanding of the
adenosine pathway with a focused
clinical plan

Expansive and differentiated development pipeline expected to make significant progress over 2023



* Planned Study

EOS-448 / GSK4428859A

iTeos and GSK are positioned to leverage the TIGIT/CD226 axis

**Why
TIGIT**

Validated target in two randomized trials with broad potential.

**Why
EOS-448**


Antibody optimized to activate multiple types of immune cells.

**Why
iTeos & GSK**


\$2B collaboration enabling a differentiated and expansive clinical development plan with unique and rational combinations.

Anti-TIGIT antibody with best-in-class properties and active Fc to induce multiple types of immune response


Maximize activity by leveraging both ends of antibody



Antibody design translates into preclinical differentiation



Antibody design translates to reduction in immunosuppressive cells in patient tumors




EOS-448 monotherapy mediates 2- to 4- fold reduction of tumor infiltrating TIGIT+ Tregs cells

GSK's PD-1 dostarlimab is the ideal combination partner for EOS-448

Dostarlimab has proven activity in lung, rectal and endometrial cancers




Dostarlimab demonstrated compelling efficacy profile in head-to-head trial compared to Pembrolizumab




PERLA Study (PFS data above): Randomized, double blind phase 2 trial of 1L treatment for metastatic non-squamous NSCLC (N=243)

EOS-448: IgG1 antibody targeting TIGIT



U.S. annual incidence



Source: Kantar, iTeos internal analysis

Clinical strategy: Differentiating to win

1. Leveraging high-quality doublet with dostarlimab in major indications
2. Additional novel doublets beyond PD-1
3. Unique triplets expanding opportunities

* Planned Study

Adenosine pathway


iTeos has developed a unique approach to unlock this important immunosuppressive pathway

Leveraging unique understanding of adenosine pathway to realize full potential

Why Adenosine Pathway	Major mechanism of immunosuppression with recent clinical validation.
Why Inupadenant	Uniquely designed for activity in solid tumors.
Why iTeos	Deep understanding of the adenosine pathway leading to potential patient selection biomarkers. Identification of new target: First-in-class EOS-984 entering clinic.

Best-in-Class profile: Inupadenant optimized for activity at high adenosine concentration found in tumors


Very high concentrations of adenosine in multiple tumor types



Human primary tumor resections; Adenosine quantified by quantitative mass-spec imaging (QMSI)


iTeos Therapeutics internal data

Insurmountable, highly selective A_{2A}R antagonist



iteostherapeutics.com

Clinical activity indicates potential of iTeos-discovered biomarker to guide patient selection



Presented at the ASCO 2021 Annual Meeting

Biomarker case study

Ongoing partial response with inupadenant monotherapy in patient with highest biomarker level observed to date

Tumor: Adenocarcinoma of unknown origin

Prior progression on three lines: radiation, chemotherapy and PD-1

Target lesion	Baseline	1 st scan	2 nd scan
Subcarinal lymph node	15	14	11
Right hilar lymph node	15	15	10
% Reduction		3%	30%

iTeos Therapeutics internal data

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Inupadenant: Small molecule targeting A_{2A} receptor

Monotherapy | High Biomarker

+ pembrolizumab | PD-1 Resistant Melanoma

+ chemotherapy | Post-IO Chemo-naïve NSCLC

EOS-984: Small molecule targeting a new mechanism in adenosine pathway

Monotherapy | Advanced Malignancies *

Clinical strategy:


1. Focused development of inupadenant in post-IO chemo-naïve NSCLC
2. Further evaluation of predictive biomarker
3. First-in-class program (EOS-984) entering clinic

*Planned Study

iTeos' Mission: We Build Better Drugs

2023 Outlook:

- Pivotal year for TIGIT
- EOS-448: Optimized active TIGIT antibody with unique development plans
- Inupadenant & EOS-984: Designed to exploit the adenosine pathway



iTEOS
THERAPEUTICS

Thank You

Nasdaq: ITOS January 2023